Osteopore Ltd. · ASX:OSX
Osteopore — Investor Presentation (November 2020)
13 slides from Osteopore's investor presentation, Nov 24, 2020
Slide 1: Investor Presentation – November 2020
For personal use only Breakthrough 3D printed bioresorbable implants to assist with the natural stages of bone healing. Osteopore Limited (ASX: OSX) Investor Presentation – November 2020
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not tr
Slide 3: Company Overview
Osteopore Limited (ASX: OSX) – Company Overview For personal use only Osteopore Limited (ASX: OSX) is an Australian / Singapore-based medical technology company that specialises in the production of 3D printed bioresorbable implants to assist with the natural stages of bone healing. Osteopore’s prod
Slide 4: Corporate and Capital Structure
Osteopore Limited (ASX: OSX) Shares on Issue1 117.2m o Tight free float with current Top 20 For personal use only holding 69% of issued capital Total Options on Issue2 13.1m Corporate and o 23% shares held by Inventors, Market Cap @ $0.59c3 $62.1m Capital Structure Board, Management and Advisors EV
Slide 5: Investment Highlights
Osteopore Limited (ASX: OSX) For personal use only 5 Investment Highlights Revenue Generating Regulatory Clearance Scalable Business Model Over A$1.3m in revenues for the twelve Osteopore’s products have secured key Proven wholesale / distributor business month period to 30 June 2020, with strong re
Slide 6: Customisable 3D printed bioresorbable implants
For personal use only Customisable 3D printed bioresorbable implants to enable the natural stages of bone healing across multiple applications. Highly customisable Naturally dissolves Leaves only healthy Reduces post surgery Unlikely inflammation to biomimic different over time bone tissue complicat
Slide 7: Strategic Milestones Since IPO
Osteopore Limited (ASX: OSX) Strategic Milestones Since IPO For personal use only Osteopore has achieved significant strategic milestones since IPO Secured multiple Gained Australian Established Success in Well funded and Distribution TGA approval for partnership for orthopaedic continuing to build
Slide 8: Quarterly Revenue Growth
Osteopore Limited (ASX: OSX) Quarterly Revenue Growth For personal use only Strong and extended sales growth since IPO, despite difficult global macroeconomic environment caused by COVID-19 o Known seasonality in sales o Quarterly sales growth 40% - 60% over previous year values o Over S$1m in sales
Slide 9: Revenue Growth Strategy
Osteopore Limited (ASX: OSX) 9 Revenue Growth Strategy For personal use only Osteopore is now looking to build value through short, medium and long term strategic goals. Revenue Expansion o Growth in revenue from existing Asian markets Phase One Increase underlying revenue from its o Establish new g
Slide 10: Opportunities in Multi-Billion Dollar Global Markets
Osteopore Limited (ASX: OSX) Opportunities in Multi-Billion Dollar Global Markets For personal use only Current Sales Current sales of Osteopore products are pre-dominantly in Cranial / Maxillofacial (CMF) area, which represents Current market opportunities less than 20% of the total Bone Graft Subs
Slide 11: FY2021 Strategic Commercial Priorities
Osteopore Limited (ASX: OSX) For personal use only 11 FY2021 Strategic Commercial Priorities 1 2 3 US Market Penetration New Markets Revenue Growth Build market penetration through existing Establish new geographic markets in Australia, Increase underlying revenue from current distributor and develo
Slide 12: Founder, Management and Board of Directors
Osteopre Limited (ASX: OSX) Partner of Ventnor Capital, Brett Sandercock Non-Executive Chairman or Director of a number of For personal use only Founder, Management Non-Exec Chairman ASX listed entities and Board of Directors Current CFO of Resmed (ASX:RMD / NYSE: RMD) Stuart Carmichael Non-Exec Dir
Slide 13: For personal use only
Investor Presentation 2020 For personal use only Goh Khoon Seng Geoff Pocock Chief Executive Officer Executive Director M +65 9670 0812 M +61 412 194 373 E: goh_khoon_seng@osteopore.com E: geoff_pocock@osteopore.com